The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,292.00
Bid: 12,288.00
Ask: 12,292.00
Change: -78.00 (-0.63%)
Spread: 4.00 (0.033%)
Open: 12,326.00
High: 12,428.00
Low: 12,276.00
Prev. Close: 12,370.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Australia backs Pfizer virus vaccine over AstraZeneca for under-50s

Thu, 08th Apr 2021 02:20

* Policy shift will hold up vaccination campaign, says PM

* People with first shot should still get their second

* Italy, UK have suggested AstraZeneca shot age limits
(Adds quote from chief health officer, prime minister and adds
detail)

By Colin Packham and Jonathan Barrett

CANBERRA/SYDNEY, April 8 (Reuters) - Australia said on
Thursday it now recommends people under 50 should get Pfizer's
COVID-19 vaccine in preference to AstraZeneca's
shot, a policy shift that it warned would hold up its
inoculation campaign.

The move, a day after European regulators reiterated they
had found possible links between AstraZeneca's shot and reports
of very rare cases of blood clots, is a huge hurdle for
Australia's programme, which had relied on that vaccine.

Australia's Chief Medical Officer, Paul Kelly, told
reporters the risk of clots was extremely low.

"It's only been found in the first dose of the AstraZeneca
vaccine, usually within 4 to 10 days after that vaccine. But it
is serious, and it can cause up to a 25% death rate when it
occurs," he said.

Australia would advise health providers to only give a first
dose of the AstraZeneca vaccine to adults younger than 50 when
the benefit clearly outweighs the risks, he added.

Italy and Britain on Wednesday joined other countries in
suggesting age limits for AstraZeneca's vaccine. But the
European regulators reaffirmed the importance of that shot in
protecting people against COVID-19.

Those who have already had a first AstraZeneca dose without
any serious adverse events "can safely be given their second
dose," Kelly said.

Prime Minister Scott Morrison said the updated advice will
delay Australia's inoculation timetable, but it was too soon to
say when Canberra would now vaccinate its adult population.

"There will be a recalibration of how the programme will
need to be adjusted," Morrison told reporters in Canberra.

Australia has ordered 20 million doses of the Pfizer vaccine
and Morrison said Canberra was in talks to increase the order.

Authorities will continue to give the AstraZeneca vaccine to
people over 70. Those over 50 who opt for the Pfizer vaccine
will have to wait, the government said.

Australia - which had planned to use the AstraZeneca vaccine
for the vast majority of its near 26 million population -
expected to give all adults at least one shot by October.

But its immunisation campaign was already heavily behind
schedule.

It had pledged to administer at least 4 million first doses
by the end of March, but could only deliver 670,000, with the
government blaming the delay on supply issues in Europe.

It had been looking to ramp up the immunisation effort,
underpinned by plans to make 50 million doses of AstraZeneca
vaccine in Australia, produced by CSL Ltd.

Australia began vaccinations much later than some other
nations because of its few infections, which stand at just under
29,400, with 909 deaths, since the pandemic began.

(Global vaccination tracker: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access/)

(Interactive graphic tracking global spread of coronavirus:
https://graphics.reuters.com/world-coronavirus-tracker-and-maps/)

(Reporting by Colin Packham and Jonathan Barrett; Editing by
Michael Perry, Clarence Fernandez and Andrew Heavens)

More News
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.